U Schopfer

Summary

Affiliation: Novartis Institutes for BioMedical Research

Publications

  1. ncbi request reprint The Novartis compound archive -- from concept to reality
    U Schopfer
    Compound Logistics and Properties Unit Novartis Compound Archive, Novartis Institutes for BioMedical Research, CH 4002 Basel, Switzerland
    Comb Chem High Throughput Screen 8:513-9. 2005
  2. ncbi request reprint Compound Hub: efficiency gains through innovative sample management processes
    Ulrich Schopfer
    Novartis Institutes for BioMedical Research, Discovery Technologies, Basel, Switzerland
    Comb Chem High Throughput Screen 10:283-7. 2007
  3. ncbi request reprint Screening library evolution through automation of solution preparation
    U Schopfer
    Lead Finding Center, Novartis Institutes for BioMedical Research, Postfach, Basel, Switzerland
    J Biomol Screen 12:724-32. 2007
  4. ncbi request reprint Molecular diversity management strategies for building and enhancement of diverse and focused lead discovery compound screening collections
    A Schuffenhauer
    Novartis Institutes for BioMedical Research Basel, Discovery Technologies, Compound Logistics and Properties Unit, Molecular and Library Informatics Program, CH 4002 Basel, Switzerland
    Comb Chem High Throughput Screen 7:771-81. 2004
  5. ncbi request reprint Key aspects of the Novartis compound collection enhancement project for the compilation of a comprehensive chemogenomics drug discovery screening collection
    Edgar Jacoby
    Novartis Institutes for BioMedical Research, CH 4002 Basel, Switzerland
    Curr Top Med Chem 5:397-411. 2005
  6. doi request reprint Stability of screening compounds in wet DMSO
    Caroline Engeloch
    Novartis Institutes for BioMedical Research, Basel, Switzerland
    J Biomol Screen 13:999-1006. 2008
  7. ncbi request reprint Closing the gap between centralized and decentralized compound management approaches
    Marc R M Andreae
    Novartis Institutes for BioMedical Research, Center for Proteomic Chemistry, Basel, Switzerland
    Comb Chem High Throughput Screen 11:825-33. 2008
  8. doi request reprint Hypothesis-driven screening
    Ulrich Schopfer
    Novartis Institutes for BioMedical Research, Novartis Pharma AG, Basel, Switzerland
    Methods Mol Biol 575:297-316. 2009
  9. doi request reprint Knowledge-based virtual screening: application to the MDM4/p53 protein-protein interaction
    Edgar Jacoby
    Novartis Institutes for BioMedical Research, Novartis Pharma AG, Basel, Switzerland
    Methods Mol Biol 575:173-94. 2009

Detail Information

Publications9

  1. ncbi request reprint The Novartis compound archive -- from concept to reality
    U Schopfer
    Compound Logistics and Properties Unit Novartis Compound Archive, Novartis Institutes for BioMedical Research, CH 4002 Basel, Switzerland
    Comb Chem High Throughput Screen 8:513-9. 2005
    ....
  2. ncbi request reprint Compound Hub: efficiency gains through innovative sample management processes
    Ulrich Schopfer
    Novartis Institutes for BioMedical Research, Discovery Technologies, Basel, Switzerland
    Comb Chem High Throughput Screen 10:283-7. 2007
    ....
  3. ncbi request reprint Screening library evolution through automation of solution preparation
    U Schopfer
    Lead Finding Center, Novartis Institutes for BioMedical Research, Postfach, Basel, Switzerland
    J Biomol Screen 12:724-32. 2007
    ..In presenting an automation concept, they show how a series of innovative process optimizations led to a high-performance system that achieves full industrialization of solution preparation...
  4. ncbi request reprint Molecular diversity management strategies for building and enhancement of diverse and focused lead discovery compound screening collections
    A Schuffenhauer
    Novartis Institutes for BioMedical Research Basel, Discovery Technologies, Compound Logistics and Properties Unit, Molecular and Library Informatics Program, CH 4002 Basel, Switzerland
    Comb Chem High Throughput Screen 7:771-81. 2004
    ..In addition to the selection methods on a per single molecule basis, selection criteria for scaffold and combinatorial chemistry projects in collaboration with compound vendors are discussed...
  5. ncbi request reprint Key aspects of the Novartis compound collection enhancement project for the compilation of a comprehensive chemogenomics drug discovery screening collection
    Edgar Jacoby
    Novartis Institutes for BioMedical Research, CH 4002 Basel, Switzerland
    Curr Top Med Chem 5:397-411. 2005
    ..Herein, we will summarize together with new trends published in the literature, scientific challenges faced and key approaches taken at NIBR to match the chemical and biological spaces...
  6. doi request reprint Stability of screening compounds in wet DMSO
    Caroline Engeloch
    Novartis Institutes for BioMedical Research, Basel, Switzerland
    J Biomol Screen 13:999-1006. 2008
    ..In addition, the authors describe how purity data collected over the course of the chemical validation of high-throughput screening actives are used to improve the analytical quality of the Novartis screening deck...
  7. ncbi request reprint Closing the gap between centralized and decentralized compound management approaches
    Marc R M Andreae
    Novartis Institutes for BioMedical Research, Center for Proteomic Chemistry, Basel, Switzerland
    Comb Chem High Throughput Screen 11:825-33. 2008
    ..The developed backend system and centralized data management facilitates the operation and integration of the stores into an existing store environment...
  8. doi request reprint Hypothesis-driven screening
    Ulrich Schopfer
    Novartis Institutes for BioMedical Research, Novartis Pharma AG, Basel, Switzerland
    Methods Mol Biol 575:297-316. 2009
    ..We demonstrate the power of hypothesis-based screening in three chemogenomics studies that were recently conducted...
  9. doi request reprint Knowledge-based virtual screening: application to the MDM4/p53 protein-protein interaction
    Edgar Jacoby
    Novartis Institutes for BioMedical Research, Novartis Pharma AG, Basel, Switzerland
    Methods Mol Biol 575:173-94. 2009
    ..Novel, selective and dual hits are discovered for both systems. A hit rate analysis will be provided compared to the full HTS (High-throughput Screening)...